Literature DB >> 15776423

Thirty-four novel mutations of the GLA gene in 121 patients with Fabry disease.

Ellen Schäfer1, Karin Baron, Urs Widmer, Patrick Deegan, Hartmut P H Neumann, Gere Sunder-Plassmann, Jan-Ove Johansson, Catharina Whybra, Markus Ries, Gregory M Pastores, Atul Mehta, Michael Beck, Andreas Gal.   

Abstract

Fabry disease (FD) is an X-chromosomal disorder caused by mutations in the GLA gene encoding the lysosomal enzyme alpha-galactosidase A. We performed mutation screening on a cohort of 121 patients including 84 male and 37 female index cases and identified a total of 90 different mutations, 34 of which are reported for the first time here. Both point mutations (74.4%) and 'short length' rearrangements (25.6%) were found, including missense (54.4%), nonsense (14.4%), and splice site point mutations (5.6%), deletions (17.8%) or insertions/duplications (5.6%) of a few nucleotides, and complex rearrangements including larger deletions (2.2%). GLA mutations were identified in 82 (97.6%) of the 84 unrelated male patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15776423     DOI: 10.1002/humu.9327

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  18 in total

Review 1.  Restrictive cardiomyopathy in a patient with systemic sclerosis and Fabry disease: a case-based review.

Authors:  Álvaro Arbeláez-Cortés; Diana C Quintero-González; Yesid Cuesta-Astroz; Juan S Villadiego; Herman González-Buriticá; Jorge M Rueda
Journal:  Rheumatol Int       Date:  2019-10-10       Impact factor: 2.631

2.  Functional analysis of variant lysosomal acid glycosidases of Anderson-Fabry and Pompe disease in a human embryonic kidney epithelial cell line (HEK 293 T).

Authors:  Hatim Y Ebrahim; Robert J Baker; Atul B Mehta; Derralynn A Hughes
Journal:  J Inherit Metab Dis       Date:  2011-10-05       Impact factor: 4.982

3.  The alpha-galactosidase A p.Arg118Cys variant does not cause a Fabry disease phenotype: data from individual patients and family studies.

Authors:  Susana Ferreira; Alberto Ortiz; Dominique P Germain; Miguel Viana-Baptista; António Caldeira-Gomes; Marta Camprecios; Maria Fenollar-Cortés; Ángel Gallegos-Villalobos; Diego Garcia; José Antonio García-Robles; Jesús Egido; Eduardo Gutiérrez-Rivas; José Antonio Herrero; Sebastián Mas; Raluca Oancea; Paloma Péres; Luis Manuel Salazar-Martín; Jesús Solera-Garcia; Helena Alves; Scott C Garman; João Paulo Oliveira
Journal:  Mol Genet Metab       Date:  2014-11-09       Impact factor: 4.797

4.  Targeted analysis of whole genome sequence data to diagnose genetic cardiomyopathy.

Authors:  Jessica R Golbus; Megan J Puckelwartz; Lisa Dellefave-Castillo; John P Fahrenbach; Viswateja Nelakuditi; Lorenzo L Pesce; Peter Pytel; Elizabeth M McNally
Journal:  Circ Cardiovasc Genet       Date:  2014-09-01

5.  Structure-function relationships in alpha-galactosidase A.

Authors:  Scott C Garman
Journal:  Acta Paediatr       Date:  2007-04       Impact factor: 2.299

6.  Fabry disease: GLA deletion alters a canonical splice site in a family with neuropsychiatric manifestations.

Authors:  Patrícia Varela; Gerson Carvalho; Renan Paulo Martin; João Bosco Pesquero
Journal:  Metab Brain Dis       Date:  2020-11-06       Impact factor: 3.584

7.  Structural characterization of mutant alpha-galactosidases causing Fabry disease.

Authors:  Kanako Sugawara; Kazuki Ohno; Seiji Saito; Hitoshi Sakuraba
Journal:  J Hum Genet       Date:  2008-07-17       Impact factor: 3.172

8.  Long-term effectiveness of enzyme replacement therapy in Fabry disease: results from the NCS-LSD cohort study.

Authors:  L J Anderson; K M Wyatt; W Henley; V Nikolaou; S Waldek; D A Hughes; G M Pastores; S Logan
Journal:  J Inherit Metab Dis       Date:  2014-05-15       Impact factor: 4.982

9.  Twenty-four-month alpha-galactosidase A replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters.

Authors:  J W Koskenvuo; J J Hartiala; P Nuutila; R Kalliokoski; J S Viikari; E Engblom; M Penttinen; J Knuuti; I Mononen; I M Kantola
Journal:  J Inherit Metab Dis       Date:  2008-05-23       Impact factor: 4.750

10.  Screening for Fabry disease in left ventricular hypertrophy: documentation of a novel mutation.

Authors:  Ana Baptista; Pedro Magalhães; Sílvia Leão; Sofia Carvalho; Pedro Mateus; Ilídio Moreira
Journal:  Arq Bras Cardiol       Date:  2015-08-07       Impact factor: 2.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.